This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pegylated Interferon to Treat Chronic Hepatitis D

This study has been completed.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ) Identifier:
First received: September 3, 2001
Last updated: July 9, 2013
Last verified: July 2013
Results First Received: April 15, 2013  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Hepatitis D
Intervention: Drug: Peginterferon Alpha-2a

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Peginterferon Alpha-2a Patients with hepatitis D virus (HDV) infection are treated with pegylated alpha interferon therapy for 3 years. The dose of the drug is 180 mcg/week.

Baseline Measures
   Peginterferon Alpha-2a 
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Median (Full Range)
 (18 to 58) 
[Units: Participants]
Female   2 
Male   11 
Race (NIH/OMB) 
[Units: Participants]
American Indian or Alaska Native   2 
Asian   0 
Native Hawaiian or Other Pacific Islander   0 
Black or African American   0 
White   11 
More than one race   0 
Unknown or Not Reported   0 
Region of Enrollment 
[Units: Participants]
United States   13 
Estimated duration of the disease [1] 
[Units: Years]
Median (Full Range)
 (7 to 35) 
[1] Estimated duration of the HDV infection
ALT [1] 
[Units: IU/L]
Median (Full Range)
 (31 to 506) 
[1] alanine aminotransferase
Infection source 
[Units: Participants]
IV Drug Abuse   6 
Sexual   2 
Transfusion   2 
Endemic Region   5 
HDV-RNA [1] 
[Units: Log10 Genome Equivalent/ml]
Mean (Standard Deviation)
 6.7  (1.2) 
[1] hepatitis D virus RNA
[Units: Log10 IU/ml]
Mean (Standard Deviation)
 3.7  (0.6) 
HBV-DNA [1] 
[Units: Log10 IU/ml]
Median (Full Range)
 (2 to 49) 
[1] hepatitis B virus DNA
Fibrosis (Ishak score) [1] 
[Units: Scores on a scale]
Median (Full Range)
 (3 to 6) 
[1] Possible range of Ishak score is 0 to 6. Higher values indicate worse outcome.

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Histological Response at 3 Years   [ Time Frame: 3 years ]

2.  Secondary:   Histological Response at 5 Years   [ Time Frame: 5 years ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information